Glukokortikoid-Therapie bei rheumatoider Arthritis – Contra

Zusammenfassung

Glukokortikoide wirken pleiotrop und beeinflussen eine Vielzahl von zellulären Funktionen. Dies resultiert nicht nur in einem breiten therapeutischen Effekt, sondern auch in einer Vielzahl von unerwünschten Wirkungen. Eine Untersuchung hat gezeigt, dass in Deutschland ca. 60 % der Patienten mit rheumatoider Arthritis (RA) Glukokortikoide erhalten, davon ca. jeder Fünfte mehr als 7,5 mg / d Prednisonäquivalent. Bereits in niedrigen Dosen erhöhen Glukokortikoide aber schon erheblich das Risiko z. B. für Osteoporose oder Katarakt, wie auch das für schwere Infektionen. Der Nutzen einer niedrig-dosierten Glukokortikoidtherapie durch Hemmung der radiologischen Erosivität der RA ist dagegen gering und wirkt die Risiken nicht auf.

Abstract

Corticosteroids have a pleiotropic mechanism of action and influence a great number of cellular functions. This does not only result in a broad therapeutic effect, but in a large number of adverse events as well. It has been shown that about 60 % of all patients with rheumatoid arthritis in Germany are receiving corticosteroids and about every fifth of them more than the equivalence of 7.5 mg prednisone per day. Already small doses increase the risk f. e. for osteoporosis or cataract, as well as for severe infections. The benefit of a treatment with low dose corticosteroids in inhibiting the radiological erosivity of the disease is low and does not outweigh the risks.

Schlüsselwörter

Glukokortikoide - rheumatoide Arthritis - Infektionen - Osteoporose

Keywords

corticosteroids - rheumatoid arthritis - infections - osteoporosis

• Literatur

• 1 Thiele K, Buttgereit F, Huscher D et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005; 53: 740-747
• 2 Huscher D, Sengler C, Gromnica-Ihle E et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 2013; 31: 256-262
• 3 Huscher D, Thiele K, Gromnica-Ihle E et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-1124
• 4 van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000; 39: 1383-1389
• 5 Zink A, Manger B, Kaufmann J et al. Evaluation of the RABBIT Risk Score for serious infections. Ann Rheum Dis 2014; 73: 1673-1676
• 6 Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 2011; 70: 1914-1920
• 7 Crowson CS, Hoganson DD, Fitz-Gibbon PD et al. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2847-2855
• 8 Dixon WG, Kezouh A, Bernatsky S et al. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011; 70: 956-960
• 9 Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010; 62: 2852-2863
• 10 Wassenberg S, Rau R, Steinfeld P et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380
• 11 Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005; 52: 3360-3367